Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FreeStyle Navigator Trial To Delay Abbott’s CGMS Debut

This article was originally published in The Gray Sheet

Executive Summary

Abbott/TheraSense has pushed back its planned launch of the Freestyle Navigator continuous blood glucose monitor until the second half of 2005

You may also be interested in...



Continuous Glucose Monitor Market Remains In Abbott’s Sights

Abbott says an FDA inspection of one third-party supplier is the only remaining barrier to PMA approval for its long-delayed Freestyle Navigator continuous glucose monitor

Continuous Glucose Monitor Market Remains In Abbott’s Sights

Abbott says an FDA inspection of one third-party supplier is the only remaining barrier to PMA approval for its long-delayed Freestyle Navigator continuous glucose monitor

Diabetes Market May Top $1 Bil. With Stick Replacement Claim – Abbott

Abbott Labs expects its Freestyle Navigator to be the first continuous blood glucose monitor approved in the U.S. as a replacement for traditional fingerstick tests

Related Content

UsernamePublicRestriction

Register

MT021036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel